Reduction Behavior Induced by HL010183, a Metformin Derivative Against the Growth of Cutaneous Squamous Cell Carcinoma

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Mar 11

PMID 25755715

Citations 1

Authors

Guoying Miao

Baoguo Liu

Xiaohui Guo

Xike Zhang

Gui-Jing Liu

Affiliations

Soon will be listed here.

Abstract

Metformin is a biguanide widely prescribed as a first-line antidiabetic drug in type 2 diabetes mellitus patients. Animal and cellular studies support that metformin has a strong anti-proliferative effect on various cancers. Herein, we report that metformin derivative, HL010183 significantly inhibited human epidermoid A431 tumor xenograft growth in nu/nu mice, which in turn is associated with a significant reduction in proliferative biomarkers PCNA and cyclins D1/B1. Enhanced apoptotic cell death and an increase in Bax: Bcl2 ratio supported the tumor growth reduction. The mechanism of the drug effects appears to be dependent on the inhibition of nuclear factor kappa B (NFkB) and mTOR signaling pathways. Reduced enhancement of NFkB transcriptional target proteins, iNOS/COX-2 together with decreased phosphorylation of NFkB inhibitory protein IKBa were also observed. Further, AKT signaling activation was evaluated by the reduced phosphorylation at Ser473. In addition, a concomitant decrease in mTOR signaling pathway was also estimated from the reduced phosphorylation at mTOR regulatory proteins p70S6K and 4E-BP-1. Along with this, decreased phosphorylation of GSK3b, which is carried out by AKT kinases was also observed. Overall results suggested that HL010183 interrupt SCC growth via NFkB and mTOR signaling pathways.

Citing Articles

6, -Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling.

Junaid A, Lim F, Chuah L, Dolzhenko A RSC Adv. 2022; 10(21):12135-12144.

PMID: 35497593 PMC: 9050923. DOI: 10.1039/d0ra00643b.

References

Memmott R, Dennis P . LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009; 27(34):e226. DOI: 10.1200/JCO.2009.25.3963. View

Knowler W, Fowler S, Hamman R, Christophi C, Hoffman H, Brenneman A . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702):1677-86. PMC: 3135022. DOI: 10.1016/S0140-6736(09)61457-4. View

Dancey J . mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010; 7(4):209-19. DOI: 10.1038/nrclinonc.2010.21. View

Kalender A, Selvaraj A, Kim S, Gulati P, Brule S, Viollet B . Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5):390-401. PMC: 3081779. DOI: 10.1016/j.cmet.2010.03.014. View

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

Engelman J, Cantley L . Chemoprevention meets glucose control. Cancer Prev Res (Phila). 2010; 3(9):1049-52. DOI: 10.1158/1940-6207.CAPR-10-0178. View

Green A, Chapuis N, Trovati Maciel T, Willems L, Lambert M, Arnoult C . The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010; 116(20):4262-73. DOI: 10.1182/blood-2010-02-269837. View

Zoncu R, Efeyan A, Sabatini D . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2010; 12(1):21-35. PMC: 3390257. DOI: 10.1038/nrm3025. View

Klumpen H, Beijnen J, Gurney H, Schellens J . Inhibitors of mTOR. Oncologist. 2010; 15(12):1262-9. PMC: 3227930. DOI: 10.1634/theoncologist.2010-0196. View

10.

Tan B, Adya R, Chen J, Lehnert H, Sant Cassia L, Randeva H . Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2010; 96(3):808-16. DOI: 10.1210/jc.2010-1803. View

11.

Janku F, Tsimberidou A, Garrido-Laguna I, Wang X, Luthra R, Hong D . PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011; 10(3):558-65. PMC: 3072168. DOI: 10.1158/1535-7163.MCT-10-0994. View

12.

Athar M, Kopelovich L . Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res (Phila). 2011; 4(7):957-61. PMC: 3136877. DOI: 10.1158/1940-6207.CAPR-11-0266. View

13.

Wu N, Gu C, Gu H, Hu H, Han Y, Li Q . Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 2011; 58(6):482-90. DOI: 10.4149/neo_2011_06_482. View

14.

Romero I, McCormick A, McEwen K, Park S, Karrison T, Yamada S . Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2011; 119(1):61-7. PMC: 3244683. DOI: 10.1097/AOG.0b013e3182393ab3. View

15.

Ruiter R, Visser L, van Herk-Sukel M, Coebergh J, Haak H, Geelhoed-Duijvestijn P . Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2011; 35(1):119-24. PMC: 3241334. DOI: 10.2337/dc11-0857. View

16.

Currie C, Poole C, Jenkins-Jones S, Gale E, Johnson J, Morgan C . Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35(2):299-304. PMC: 3263862. DOI: 10.2337/dc11-1313. View

17.

Dowling R, Niraula S, Stambolic V, Goodwin P . Metformin in cancer: translational challenges. J Mol Endocrinol. 2012; 48(3):R31-43. DOI: 10.1530/JME-12-0007. View

18.

Hanna R, Zhou C, Malloy K, Sun L, Zhong Y, Gehrig P . Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012; 125(2):458-69. PMC: 3322276. DOI: 10.1016/j.ygyno.2012.01.009. View

19.

Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E . Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila). 2012; 5(4):536-43. DOI: 10.1158/1940-6207.CAPR-11-0536. View

20.

Bhalla K, Hwang B, Dewi R, Twaddel W, Goloubeva O, Wong K . Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila). 2012; 5(4):544-52. PMC: 3324649. DOI: 10.1158/1940-6207.CAPR-11-0228. View